Inpatient Diabetes Management: Abandon Sliding‑Scale Insulin and Implement Scheduled Basal‑Bolus Therapy

Recommendation Against Sliding‑Scale Insulin

• The American Diabetes Association (ADA) and all major diabetes guideline societies explicitly condemn the use of sliding‑scale insulin as monotherapy for any hospitalized adult (≥ 18 years) with type 1 or type 2 diabetes who requires insulin, recommending immediate replacement with a scheduled basal‑bolus regimen. [1][2]

Comparative Efficacy

• Only ≈ 38 % of patients managed with sliding‑scale insulin alone achieve a mean glucose < 140 mg/dL, compared with ≈ 68 % when a scheduled basal‑bolus regimen is used, demonstrating clear superiority of basal‑bolus therapy. 1
• Sliding‑scale insulin reacts after hyperglycemia occurs, producing wide glucose fluctuations that worsen both hyper‑ and hypoglycemia. 1

Basal‑Bolus Regimen Components

Basal Insulin

• Long‑acting insulin analogs (glargine, detemir, or degludec) given once daily provide continuous background coverage and suppress hepatic glucose production independent of food intake. [1][2]

Prandial (Meal‑time) Insulin

• Rapid‑acting analogs (lispro, aspart, or glulisine) administered 0–15 minutes before each meal effectively cover meal‑related glucose excursions. [1][2]

Correction Insulin

• Correction doses of rapid‑acting insulin are used only as a supplement to scheduled basal and prandial doses when pre‑meal glucose exceeds predefined thresholds; they are not a substitute for scheduled insulin. [1][2]

Initial Dosing Strategies

All dosing recommendations are endorsed by the ADA. [1][2]

Titration Protocols

• Basal insulin: increase by 2 U every 3 days if fasting glucose is 140–179 mg/dL; increase by 4 U every 3 days if fasting ≥ 180 mg/dL. Target fasting glucose 80–130 mg/dL. [1][2]
• Prandial insulin: increase each meal dose by 1–2 U (≈ 10–15 %) every 3 days based on 2‑hour post‑prandial glucose. Target post‑prandial glucose < 180 mg/dL. [1][2]
• If unexplained hypoglycemia (< 70 mg/dL) occurs, reduce the implicated insulin dose by 10–20 % immediately. [1][2]

Monitoring and Glycemic Targets

• Patients eating regular meals: check capillary glucose before each meal and at bedtime (≥ 4 checks/day). [1][2]
• Patients with poor intake or NPO: check glucose every 4–6 hours. [1][2]
• Daily fasting glucose is required during titration to guide basal adjustments. [1][2]
• Obtain a 2‑hour post‑prandial glucose after each meal to assess prandial adequacy. 1

Target ranges (non‑critically ill):

• Overall glucose 140–180 mg/dL. [1][2]
• More stringent 110–140 mg/dL may be used if achievable without significant hypoglycemia. [1][2]
• Fasting glucose 80–130 mg/dL and post‑prandial < 180 mg/dL. [1][2]

Hypoglycemia Management

• Treat glucose < 70 mg/dL promptly with 15 g of fast‑acting carbohydrate, re‑check in 15 minutes, and repeat if needed. [1][2]
• After an unexplained hypoglycemic event, reduce the implicated insulin dose by 10–20 % before the next administration. [1][2]
• Document every hypoglycemic episode in the medical record and track for quality‑improvement. [1][2]

Special Situations

Patients with Poor Oral Intake or NPO

• Use a basal‑plus‑correction regimen: basal insulin once daily at a reduced dose (0.1–0.25 U/kg/day for high‑risk patients) plus correction doses only when glucose exceeds set thresholds. [1][2]
• Never withhold basal insulin in patients with type 1 diabetes or insulin‑dependent type 2 diabetes, even when NPO, to prevent diabetic ketoacidosis. [1][2]

Peri‑operative Management

• On the morning of surgery, give 50 % of the usual NPH dose or 75–80 % of the usual long‑acting analog dose to reduce hypoglycemia risk while maintaining target glucose. [1][2]
• While NPO peri‑operatively, monitor glucose every 2–4 hours and supplement with short‑ or rapid‑acting insulin as needed. [1][2]
• Aim for a peri‑operative glucose range of 80–180 mg/dL. [1][2]

Transition from Intravenous Insulin

• Administer subcutaneous basal insulin 2–4 hours before stopping the IV infusion to avoid rebound hyperglycemia and recurrent ketoacidosis. [1][2]
• Convert to basal insulin at 60–80 % of the total daily IV dose (or half of the 24‑hour IV amount), splitting the dose 50 % basal and 50 % prandial. 1

Critically Ill Patients

• Continuous intravenous insulin infusion is the preferred method; target glucose 140–180 mg/dL for the majority of critically ill patients. [1][2]
• Initiate insulin therapy when glucose persistently exceeds 180 mg/dL. [1][2]

Expected Clinical Outcomes

• With correctly applied basal‑bolus therapy, ≈ 68 % of hospitalized patients achieve mean glucose < 140 mg/dL versus ≈ 38 % on sliding‑scale alone. 1
• Basal‑bolus therapy does not increase hypoglycemia incidence when titrated appropriately, compared with sliding‑scale monotherapy. 1

Pitfalls to Avoid (ADA Guidance)

• Do not use sliding‑scale insulin as monotherapy in any hospitalized patient. [1][2]
• Do not give rapid‑acting insulin at bedtime as a sole correction dose (risk of nocturnal hypoglycemia). [1][2]
• Do not delay adding prandial insulin when basal insulin alone fails to meet fasting targets or when basal dose reaches 0.5–1.0 U/kg/day without achieving goals. [1][2]
• Do not continue basal insulin escalation beyond 0.5–1.0 U/kg/day without addressing post‑prandial hyperglycemia (avoids “over‑basalization”). [1][2]
• Do not rely solely on correction doses without adjusting scheduled basal and prandial insulin. [1][2]
• Do not use sliding‑scale insulin as the sole treatment in type 1 diabetes (risk of diabetic ketoacidosis). [1][2]

Insulin Regimens for Managing Hyperglycemia

Introduction to Insulin Regimens

• The American Diabetes Association recommends basal-bolus insulin regimens over sliding scale insulin alone for managing hyperglycemia in hospitalized patients, as SSI alone is ineffective and strongly discouraged in clinical guidelines 3, 4

Types of Sliding Scale Insulin Regimens

• Lower-dose sliding scale insulin regimens are used for patients at higher risk of hypoglycemia, including older patients (>65 years), those with renal failure, or poor oral intake, and typically start with smaller insulin doses (e.g., 1-2 units) for lower blood glucose elevations 4, 5
• The basal-plus approach, which consists of a single dose of basal insulin (0.1-0.25 U/kg per day) along with correctional doses of rapid-acting insulin, is preferred for patients with mild hyperglycemia, decreased oral intake, or those undergoing surgery 4, 5

Evidence-Based Recommendations

• Randomized trials consistently show better glycemic control with basal-bolus approach than with sliding scale insulin alone, with a significant difference in mean blood glucose levels 4, 5
• The basal-bolus approach achieved target glucose control in 68% of patients versus only 38% with sliding scale insulin alone 6

Safety Considerations

• The incidence of mild iatrogenic hypoglycemia with basal-bolus approach is about 12-30% in controlled settings, and for patients treated with higher doses of insulin at home (≥0.6 U/kg per day), a 20% reduction in total daily insulin dose is recommended during hospitalization to prevent hypoglycemia 4

Recommended Approaches by Patient Type

• For critically ill patients, continuous intravenous insulin infusion is the most effective method for achieving glycemic targets, with a target blood glucose range of 140-180 mg/dL 3, 7, 8
• For non-critically ill patients with good nutritional intake, basal-bolus insulin regimen is preferred, with a total daily insulin dose between 0.3-0.5 U/kg for insulin-naive patients 3, 4, 8
• For non-critically ill patients with poor oral intake or NPO, basal insulin or basal-plus-correction insulin regimen is preferred, with a lower total daily dose (0.1-0.25 U/kg per day) plus correction doses 3, 4, 5, 8

Common Pitfalls to Avoid

• Using SSI alone for patients with type 1 diabetes is dangerous and should never be done, and continuing the same sliding scale regimen throughout hospitalization without modification despite poor control should be avoided 4, 5, 6, 9
• Premixed insulin therapy (human insulin 70/30) has been associated with unacceptably high rates of hypoglycemia and is not recommended in the hospital, and relying solely on sliding scale insulin creates a "reactive" approach that leads to glucose variability rather than stable control 4, 6, 9
• Failing to adjust insulin doses when transitioning from critical to non-critical care settings should be avoided 10, 11